GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A3592 Medetomidine1 CitationSummary: α2-adrenoceptor agonist -
A3601 mGlu2 agonistSummary: Anti-depressants,novel potent agent -
A3608 MK 0893Target: Insulin and Insulin-like Receptors|Glucagon ReceptorsSummary: A competitive, reversible glucagon receptor (GCGR) antagonist -
A3611 MK-0812Summary: antagonist of chemokine receptor CCR-2 -
A3613 MK-2894Summary: EP4 receptor inhibitor -
A3623 MK-6892Summary: Highly potential GPR109A agonist -
A3633 MPEP HydrochlorideTarget: Glutamate (Metabotropic) Group I ReceptorsSummary: MGlu5 receptor antagonist -
A3636 MTEP hydrochlorideSummary: MGlu5 antagonist -
A3667 NPS-2143 hydrochlorideTarget: Calcium-Sensing Receptors (CaSRs)Summary: Calcium ion-sensing receptor antagonist -
B4979 Octreotide acetateSummary: octapeptide congener of native somatostatin

